share_log

Needham Reiterates Buy on BioCryst Pharma, Lowers Price Target to $12

Needham Reiterates Buy on BioCryst Pharma, Lowers Price Target to $12

Needham 重申买入 BioCryst Pharma,将目标股价下调至 12 美元
Benzinga ·  2023/08/03 13:27

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the price target from $14 to $12.

Needham分析师塞尔吉·贝兰格重申了BioCryst Pharma(纳斯达克股票代码:BCRX)的买入,并将目标股价从14美元下调至12美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发